BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 33373589)

  • 1. Salvage Surgery Post Definitive Chemoradiotherapy and Durvalumab for Lung Cancer.
    Minegishi K; Tsubochi H; Ohno K; Komori K; Ozeki M; Endo S
    Ann Thorac Surg; 2021 Jul; 112(1):e53-e55. PubMed ID: 33373589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathological analysis of a superior sulcus tumor treated by salvage surgery after concurrent definitive chemoradiotherapy followed by durvalumab: A case report.
    Funaki S; Ose N; Kimura T; Kanou T; Fukui E; Shintani Y
    Thorac Cancer; 2022 Nov; 13(22):3229-3232. PubMed ID: 36193676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feasibility of salvage resection following locoregional failure after chemoradiotherapy and consolidation durvalumab for unresectable stage III non-small cell lung cancer.
    Dickhoff C; Unal S; Heineman DJ; Winkelman JA; Braun J; Bahce I; van Dorp M; Senan S; Dahele M
    Lung Cancer; 2023 Aug; 182():107294. PubMed ID: 37442060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world prospective analysis of treatment patterns in durvalumab maintenance after chemoradiotherapy in unresectable, locally advanced NSCLC patients.
    Taugner J; Käsmann L; Eze C; Rühle A; Tufman A; Reinmuth N; Duell T; Belka C; Manapov F
    Invest New Drugs; 2021 Aug; 39(4):1189-1196. PubMed ID: 33704621
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patients with unresectable stage III non-small cell lung cancer eligible to receive consolidation therapy with durvalumab in clinical practice based on PACIFIC study criteria.
    Sakaguchi T; Ito K; Furuhashi K; Nakamura Y; Suzuki Y; Nishii Y; Taguchi O; Hataji O
    Respir Investig; 2019 Sep; 57(5):466-471. PubMed ID: 31104989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Salvage Lung Resections After Definitive Chemoradiotherapy: A Safe and Effective Oncologic Option.
    Bograd AJ; Mann C; Gorden JA; Gilbert CR; Farivar AS; Aye RW; Louie BE; Vallières E
    Ann Thorac Surg; 2020 Oct; 110(4):1123-1130. PubMed ID: 32473131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salvage Surgery After Definitive Chemoradiotherapy for Non-small Cell Lung Cancer.
    Casiraghi M; Maisonneuve P; Piperno G; Bellini R; Brambilla D; Petrella F; Marinis F; Spaggiari L
    Semin Thorac Cardiovasc Surg; 2017 Summer; 29(2):233-241. PubMed ID: 28823336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current status and progress of concurrent chemoradiotherapy in patients with locally advanced non-small cell lung cancer prior to the approval of durvalumab.
    Fukui T; Hosotani S; Soda I; Ozawa T; Kusuhara S; Kakegawa MI; Kasajima M; Hiyoshi Y; Igawa S; Yokoba M; Mitsufuji H; Kubota M; Katagiri M; Sasaki J; Ishiyama H; Naoki K
    Thorac Cancer; 2020 Apr; 11(4):1005-1014. PubMed ID: 32057187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Consolidation treatment of durvalumab after chemoradiation in real-world patients with stage III unresectable non-small cell lung cancer.
    Chu CH; Chiu TH; Wang CC; Chang WC; Huang AC; Liu CY; Wang CL; Ko HW; Chung FT; Hsu PC; Guo YK; Kuo CS; Yang CT
    Thorac Cancer; 2020 Jun; 11(6):1541-1549. PubMed ID: 32281272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness and Budgetary Consequence Analysis of Durvalumab Consolidation Therapy vs No Consolidation Therapy After Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer in the Context of the US Health Care System.
    Criss SD; Mooradian MJ; Sheehan DF; Zubiri L; Lumish MA; Gainor JF; Reynolds KL; Kong CY
    JAMA Oncol; 2019 Mar; 5(3):358-365. PubMed ID: 30543349
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unmet Clinical Need in the Management of Locally Advanced Unresectable Lung Cancer: Treatment Strategies to Improve Patient Outcomes.
    Rajappa S; Sharma S; Prasad K
    Adv Ther; 2019 Mar; 36(3):563-578. PubMed ID: 30693419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is salvage surgery for recurrent non-small-cell lung cancer after definitive non-operative therapy associated with reasonable survival?
    Schreiner W; Dudek W; Sirbu H
    Interact Cardiovasc Thorac Surg; 2015 Nov; 21(5):682-4. PubMed ID: 26323288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DUART: durvalumab after radiotherapy in patients with unresectable, stage III NSCLC who are ineligible for chemotherapy.
    Filippi AR; Dziadziuszko R; García Campelo MR; Paoli JB; Sawyer W; Díaz Pérez IE
    Future Oncol; 2021 Dec; 17(34):4657-4663. PubMed ID: 34775804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Feasibility and efficacy of salvage lung resection after definitive chemoradiation therapy for Stage III non-small-cell lung cancer.
    Shimada Y; Suzuki K; Okada M; Nakayama H; Ito H; Mitsudomi T; Saji H; Takamochi K; Kudo Y; Hattori A; Mimae T; Aokage K; Nishii T; Tsuboi M; Ikeda N
    Interact Cardiovasc Thorac Surg; 2016 Dec; 23(6):895-901. PubMed ID: 27543652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pre-treatment FDG-PET predicts the site of in-field progression following concurrent chemoradiotherapy for stage III non-small cell lung cancer.
    Ohri N; Piperdi B; Garg MK; Bodner WR; Gucalp R; Perez-Soler R; Keller SM; Guha C
    Lung Cancer; 2015 Jan; 87(1):23-7. PubMed ID: 25468149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Salvage surgery after definitive chemo-radiotherapy for patients with Non-Small Cell Lung Cancer.
    Romero-Vielva L; Viteri S; Moya-Horno I; Toscas JI; Maestre-Alcácer JA; Ramón Y Cajal S; Rosell R
    Lung Cancer; 2019 Jul; 133():117-122. PubMed ID: 31200817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy.
    Aredo JV; Mambetsariev I; Hellyer JA; Amini A; Neal JW; Padda SK; McCoach CE; Riess JW; Cabebe EC; Naidoo J; Abuali T; Salgia R; Loo BW; Diehn M; Han SS; Wakelee HA
    J Thorac Oncol; 2021 Jun; 16(6):1030-1041. PubMed ID: 33588109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer.
    Melosky B; Juergens R; McLeod D; Leighl N; Brade A; Card PB; Chu Q
    Lung Cancer; 2019 Aug; 134():259-267. PubMed ID: 31319991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pattern-of-failure and salvage treatment analysis after chemoradiotherapy for inoperable stage III non-small cell lung cancer.
    Taugner J; Eze C; Käsmann L; Roengvoraphoj O; Gennen K; Karin M; Petrukhnov O; Tufman A; Belka C; Manapov F
    Radiat Oncol; 2020 Jun; 15(1):148. PubMed ID: 32517716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolic patterns on [
    Holzgreve A; Taugner J; Käsmann L; Müller P; Tufman A; Reinmuth N; Li M; Winkelmann M; Unterrainer LM; Nieto AE; Bartenstein P; Kunz WG; Ricke J; Belka C; Eze C; Unterrainer M; Manapov F
    Eur J Nucl Med Mol Imaging; 2023 Jul; 50(8):2466-2476. PubMed ID: 36951991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.